246 related articles for article (PubMed ID: 29615341)
21. Synthesis and biological evaluation of 2-alkyl-2-methoxymethyl-salvinorin ethers as selective κ-opioid receptor agonists.
Lee DY; Deng G; Ma Z; Xu W; Yang L; Liu J; Dai R; Liu-Chen LY
Bioorg Med Chem Lett; 2015 Oct; 25(20):4689-92. PubMed ID: 26330078
[TBL] [Abstract][Full Text] [Related]
22. Salvinorin A: a novel and highly selective kappa-opioid receptor agonist.
Yan F; Roth BL
Life Sci; 2004 Oct; 75(22):2615-9. PubMed ID: 15369697
[TBL] [Abstract][Full Text] [Related]
23. Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist.
Roth BL; Baner K; Westkaemper R; Siebert D; Rice KC; Steinberg S; Ernsberger P; Rothman RB
Proc Natl Acad Sci U S A; 2002 Sep; 99(18):11934-9. PubMed ID: 12192085
[TBL] [Abstract][Full Text] [Related]
24. Salvinorin A: the "magic mint" hallucinogen finds a molecular target in the kappa opioid receptor.
Sheffler DJ; Roth BL
Trends Pharmacol Sci; 2003 Mar; 24(3):107-9. PubMed ID: 12628350
[TBL] [Abstract][Full Text] [Related]
25. Inhibitory effect of salvinorin A, from Salvia divinorum, on ileitis-induced hypermotility: cross-talk between kappa-opioid and cannabinoid CB(1) receptors.
Capasso R; Borrelli F; Cascio MG; Aviello G; Huben K; Zjawiony JK; Marini P; Romano B; Di Marzo V; Capasso F; Izzo AA
Br J Pharmacol; 2008 Nov; 155(5):681-9. PubMed ID: 18622408
[TBL] [Abstract][Full Text] [Related]
26. Antinociceptive and hypothermic effects of Salvinorin A are abolished in a novel strain of kappa-opioid receptor-1 knockout mice.
Ansonoff MA; Zhang J; Czyzyk T; Rothman RB; Stewart J; Xu H; Zjwiony J; Siebert DJ; Yang F; Roth BL; Pintar JE
J Pharmacol Exp Ther; 2006 Aug; 318(2):641-8. PubMed ID: 16672569
[TBL] [Abstract][Full Text] [Related]
27. Kappa-opioid receptor-mediated effects of the plant-derived hallucinogen, salvinorin A, on inverted screen performance in the mouse.
Fantegrossi WE; Kugle KM; Valdes LJ; Koreeda M; Woods JH
Behav Pharmacol; 2005 Dec; 16(8):627-33. PubMed ID: 16286814
[TBL] [Abstract][Full Text] [Related]
28. Potential anxiolytic- and antidepressant-like effects of salvinorin A, the main active ingredient of Salvia divinorum, in rodents.
Braida D; Capurro V; Zani A; Rubino T; Viganò D; Parolaro D; Sala M
Br J Pharmacol; 2009 Jul; 157(5):844-53. PubMed ID: 19422370
[TBL] [Abstract][Full Text] [Related]
29. Immediate and Persistent Effects of Salvinorin A on the Kappa Opioid Receptor in Rodents, Monitored In Vivo with PET.
Placzek MS; Van de Bittner GC; Wey HY; Lukas SE; Hooker JM
Neuropsychopharmacology; 2015 Dec; 40(13):2865-72. PubMed ID: 26058662
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and in vitro pharmacological studies of new C(4)-modified salvinorin A analogues.
Lee DY; He M; Liu-Chen LY; Wang Y; Li JG; Xu W; Ma Z; Carlezon WA; Cohen B
Bioorg Med Chem Lett; 2006 Nov; 16(21):5498-502. PubMed ID: 16945525
[TBL] [Abstract][Full Text] [Related]
31. Salvinorin A analogs and other κ-opioid receptor compounds as treatments for cocaine abuse.
Kivell BM; Ewald AW; Prisinzano TE
Adv Pharmacol; 2014; 69():481-511. PubMed ID: 24484985
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the discriminative stimulus effects of salvinorin A and its derivatives to U69,593 and U50,488 in rats.
Baker LE; Panos JJ; Killinger BA; Peet MM; Bell LM; Haliw LA; Walker SL
Psychopharmacology (Berl); 2009 Apr; 203(2):203-11. PubMed ID: 19153716
[TBL] [Abstract][Full Text] [Related]
33. Selective natural kappa opioid and cannabinoid receptor agonists with a potential role in the treatment of gastrointestinal dysfunction.
Fichna J; Schicho R; Janecka A; Zjawiony JK; Storr M
Drug News Perspect; 2009 Sep; 22(7):383-92. PubMed ID: 19890495
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the diuretic effects of chemically diverse kappa opioid agonists in rats: nalfurafine, U50,488H, and salvinorin A.
Inan S; Lee DY; Liu-Chen LY; Cowan A
Naunyn Schmiedebergs Arch Pharmacol; 2009 Mar; 379(3):263-70. PubMed ID: 18925386
[TBL] [Abstract][Full Text] [Related]
35. Salvinorin A analogs as probes in opioid pharmacology.
Prisinzano TE; Rothman RB
Chem Rev; 2008 May; 108(5):1732-43. PubMed ID: 18476672
[No Abstract] [Full Text] [Related]
36. Studies toward the pharmacophore of salvinorin A, a potent kappa opioid receptor agonist.
Munro TA; Rizzacasa MA; Roth BL; Toth BA; Yan F
J Med Chem; 2005 Jan; 48(2):345-8. PubMed ID: 15658846
[TBL] [Abstract][Full Text] [Related]
37. Semisynthesis and Kappa-Opioid Receptor Activity of Derivatives of Columbin, a Furanolactone Diterpene.
Yilmaz A; Crowley RS; Sherwood AM; Prisinzano TE
J Nat Prod; 2017 Jul; 80(7):2094-2100. PubMed ID: 28718638
[TBL] [Abstract][Full Text] [Related]
38. CoMFA analyses of C-2 position salvinorin A analogs at the kappa-opioid receptor provides insights into epimer selectivity.
McGovern DL; Mosier PD; Roth BL; Westkaemper RB
J Mol Graph Model; 2010 Apr; 28(7):612-25. PubMed ID: 20083418
[TBL] [Abstract][Full Text] [Related]
39. Comparison of pharmacological activities of three distinct kappa ligands (Salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo.
Wang Y; Tang K; Inan S; Siebert D; Holzgrabe U; Lee DY; Huang P; Li JG; Cowan A; Liu-Chen LY
J Pharmacol Exp Ther; 2005 Jan; 312(1):220-30. PubMed ID: 15383632
[TBL] [Abstract][Full Text] [Related]
40. Convenient synthesis and in vitro pharmacological activity of 2-thioanalogs of salvinorins A and B.
Bikbulatov RV; Yan F; Roth BL; Zjawiony JK
Bioorg Med Chem Lett; 2007 Apr; 17(8):2229-32. PubMed ID: 17303418
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
